Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study.

Paolo Bossi, Ketty Peris, Piergiacomo Calzavara-Pinton, Paola Queirolo, Salvatore Alfieri, Marco Palla, Maria Teresa Rossi, Francesco Spagnolo, Sara Tambone, Cinzia Astolfi, Paolo A. Ascierto

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To assess safety and efficacy of vismodegib in the Italian cohort from the SafeTy Events in VIsmodEgib study. Materials methods: Data from Italian patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC were analyzed. Results: Among 182 Italian patients, adverse events occurred with similar incidence to the overall population. Overall response rate was 67.1 20 complete response rate was 33.17.4 months in complete responders versus 3.6 months overall. Quality of life improved from baseline. Conclusion: In the Italian cohort of STEVIE, vismodegib showed a safety profile consistent with the whole population; older age did not affect safety or efficacy. ClinicalTrials.gov registration: NCT01367665.
Original languageEnglish
JournalFuture Oncology
Issue number16
Publication statusPublished - Jun 1 2020

Fingerprint Dive into the research topics of 'Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study.'. Together they form a unique fingerprint.

Cite this